|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Pignata S, Cannella L, Leopardo D, Pisano
C, Bruni GS and Facchini G: Chemotherapy in epithelial ovarian
cancer. Cancer Lett. 303:73–83. 2011. View Article : Google Scholar
|
|
3
|
Gonzalez-Martin AJ: Medical treatment of
epithelial ovarian cancer. Expert Rev Anticancer Ther. 4:1125–1143.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Matsuo K, Lin YG, Roman LD and Sood AK:
Overcoming platinum resistance in ovarian carcinoma. Expert Opin
Investig Drugs. 19:1339–1354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Altomare DA, Wang HQ, Skele KL, et al: AKT
and mTOR phosphorylation is frequently detected in ovarian cancer
and can be targeted to disrupt ovarian tumor cell growth. Oncogene.
23:5853–5857. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheng JQ, Lindsley CW, Cheng GZ, Yang H
and Nicosia SV: The Akt/PKB pathway: molecular target for cancer
drug discovery. Oncogene. 24:7482–7492. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Steelman LS, Chappell WH, Abrams SL, et
al: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in
controlling growth and sensitivity to therapy-implications for
cancer and aging. Aging. 3:192–222. 2011.PubMed/NCBI
|
|
8
|
Levine DA, Bogomolniy F, Yee CJ, et al:
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Clin Cancer Res. 11:2875–2878. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Engel JB, Schonhals T, Hausler S, et al:
Induction of programmed cell death by inhibition of AKT with the
alkylphosphocholine perifosine in in vitro models of platinum
sensitive and resistant ovarian cancers. Arch Gynecol Obstet.
283:603–610. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Santiskulvong C, Konecny GE, Fekete M, et
al: Dual targeting of phosphoinositide 3-kinase and mammalian
target of rapamycin using NVP-BEZ235 as a novel therapeutic
approach in human ovarian carcinoma. Clin Cancer Res. 17:2373–2384.
2011. View Article : Google Scholar
|
|
11
|
Westfall SD and Skinner MK: Inhibition of
phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to
carboplatin and allows adjunct chemotherapy treatment. Mol Cancer
Ther. 4:1764–1771. 2005. View Article : Google Scholar
|
|
12
|
Benedetti V, Perego P, Luca Beretta G, et
al: Modulation of survival pathways in ovarian carcinoma cell lines
resistant to platinum compounds. Mol Cancer Ther. 7:679–687. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sato S, Fujita N and Tsuruo T: Modulation
of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA.
97:10832–10837. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Katayama K, Fujita N and Tsuruo T:
Akt/protein kinase B-dependent phosphorylation and inactivation of
WEE1Hu promote cell cycle progression at G2/M transition. Mol Cell
Biol. 25:5725–5737. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Behrens BC, Hamilton TC, Masuda H, et al:
Characterization of a cis-diamminedichloroplatinum(II)-resistant
human ovarian cancer cell line and its use in evaluation of
platinum analogues. Cancer Res. 47:414–418. 1987.PubMed/NCBI
|
|
16
|
Engels K, Knauer SK, Loibl S, et al: NO
signaling confers cytoprotectivity through the survivin network in
ovarian carcinomas. Cancer Res. 68:5159–5166. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Campling PJ, Galbraith PR and Cole SP: Use
of the MTT assay for rapid determinarion of chemosensitivity of
human leukemic blast cells. Leuk Res. 12:823–831. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hayakawa J, Ohmichi M, Kurachi H, et al:
Inhibition of BAD phosphorylation either at serine 112 via
extracellular signal-regulated protein kinase cascade or at serine
136 via Akt cascade sensitizes human ovarian cancer cells to
cisplatin. Cancer Res. 60:5988–5994. 2000.
|
|
19
|
Yang X, Fraser M, Moll UM, Basak A and
Tsang BK: Akt-mediated cisplatin resistance in ovarian cancer:
modulation of p53 action on caspase-dependent mitochondrial death
pathway. Cancer Res. 66:3126–3136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fraser M, Bai T and Tsang BK: Akt promotes
cisplatin resistance in human ovarian cancer cells through
inhibition of p53 phosphorylation and nuclear function. Int J
Cancer. 122:534–546. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang X, Fraser M, Abedini MR, Bai T and
Tsang BK: Regulation of apoptosis-inducing factor-mediated,
cisplatin-induced apoptosis by Akt. Br J Cancer. 98:803–808. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Arafa el SA, Zhu Q, Barakat BM, et al:
Tangeretin sensitizes cisplatin-resistant human ovarian cancer
cells through downregulation of phosphoinositide 3-kinase/Akt
signaling pathway. Cancer Res. 69:8910–8917. 2009.
|
|
23
|
Kolasa IK, Rembiszewska A, Felisiak A, et
al: PIK3CA amplification associates with resistance to chemotherapy
in ovarian cancer patients. Cancer Biol Ther. 8:21–26. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Woenckhaus J, Steger K, Sturm K, Munstedt
K, Franke FE and Fenic I: Prognostic value of PIK3CA and
phosphorylated AKT expression in ovarian cancer. Virchows Arch.
450:387–395. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Marsh Rde W, Rocha Lima CM, Levy DE,
Mitchell EP, Rowland KM Jr and Benson AB III: A phase II trial of
perifosine in locally advanced, unresectable, or metastatic
pancreatic adenocarcinoma. Am J Clin Oncol. 30:26–31.
2007.PubMed/NCBI
|
|
26
|
Leighl NB, Dent S, Clemons M, et al: A
phase 2 study of perifosine in advanced or metastatic breast
cancer. Breast Cancer Res Treat. 108:87–92. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Snyder EL, Bailey D, Shipitsin M, Polyak K
and Loda M: Identification of CD44v6(+)/CD24− breast
carcinoma cells in primary human tumors by quantum dot-conjugated
antibodies. Lab Invest. 89:857–866. 2009.
|
|
28
|
Argiris A, Cohen E, Karrison T, et al: A
phase II trial of perifosine, an oral alkylphospholipid, in
recurrent or metastatic head and neck cancer. Cancer Biol Ther.
5:766–770. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Knowling M, Blackstein M, Tozer R, et al:
A phase II study of perifosine (D-21226) in patients with
previously untreated metastatic or locally advanced soft tissue
sarcoma: a National Cancer Institute of Canada Clinical Trials
Group trial. Invest New Drugs. 24:435–439. 2006. View Article : Google Scholar
|
|
30
|
Posadas EM, Gulley J, Arlen PM, et al: A
phase II study of perifosine in androgen independent prostate
cancer. Cancer Biol Ther. 4:1133–1137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ernst DS, Eisenhauer E, Wainman N, et al:
Phase II study of perifosine in previously untreated patients with
metastatic melanoma. Invest New Drugs. 23:569–575. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vink SR, Schellens JH, Beijnen JH, et al:
Phase I and pharmacokinetic study of combined treatment with
perifosine and radiation in patients with advanced solid tumours.
Radiother Oncol. 80:207–213. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
He G, Kuang J, Khokhar AR and Siddik ZH:
The impact of S- and G2-checkpoint response on the fidelity of
G1-arrest by cisplatin and its comparison to a non-cross-resistant
platinum(IV) analog. Gynecol Oncol. 122:402–409. 2011. View Article : Google Scholar : PubMed/NCBI
|
